Zobrazeno 1 - 10
of 43
pro vyhledávání: ''
Autor:
Jonathan D. Leavenworth, Michael L. Dixon, Sadashib Ghosh, Lin Luo, Jeffrey M. Grimes, Jianmei W. Leavenworth
Publikováno v:
Molecular Cancer, Vol 20, Iss 1, Pp 1-24 (2021)
Background Accumulation of Foxp3+ regulatory T (Treg) cells in the tumor often represents an important mechanism for cancer immune evasion and a critical barrier to anti-tumor immunity and immunotherapy. Many tumor-infiltrating Treg cells display an
Autor:
Bing Chen, Jingjing Zhao, Qin Li, Yuchen Li, Qiupeng Zheng, Hongyan Lai, Siyuan Chen, Shenglin Huang, Xiao-Dong Zhu, Yan Li
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-22 (2021)
BMC Cancer
BMC Cancer
Background Viral infections are prevalent in human cancers and they have great diagnostic and theranostic values in clinical practice. Recently, their potential of shaping the tumor immune microenvironment (TIME) has been related to the immunotherapy
Autor:
Hemavathi Dhandapani, Selvaluxmy Ganeshrajah, Priya Ramanathan, Rajkumar Thangarajan, Anil Suri, Hascitha Jayakumar, Shirley Sunder Singh, Nirmala Jagadish, Abirami Seetharaman
Publikováno v:
Cancer Cell International, Vol 21, Iss 1, Pp 1-14 (2021)
Background Dendritic cell (DC)-based immunotherapy is capable of activating the immune system and in particular tumor-specific cytotoxic T lymphocytes (CTLs) to eradicate the tumor. However, major limitations are the availability of autologous tumor
Publikováno v:
Experimental Hematology & Oncology, Vol 10, Iss 1, Pp 1-5 (2021)
Experimental Hematology & Oncology
Experimental Hematology & Oncology
We reported a patient with unresectable hepatocellular carcinoma (HCC) who initially received 15 cycles of atezolizumab plus bevacizumab combination and had best tumor response of partial response, but later experienced disease progression. After sub
Autor:
Yizhou Zhang, Yang Yu, Zhiyun Liang, Yu Tian, Baokang Wu, Heming Zhang, Qi Lang, Xin Zhao, Chongli Zhong, Feng Xu
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-16 (2021)
Journal of Experimental & Clinical Cancer Research : CR
Journal of Experimental & Clinical Cancer Research : CR
Immune checkpoint molecules, also known as cosignaling molecules, are pivotal cell-surface molecules that control immune cell responses by either promoting (costimulatory molecules) or inhibiting (coinhibitory molecules) a signal. These molecules hav
Autor:
Wuling Liu, Hemavathi Dhandapani, Xiangchun Shen, Krishnapriya M. Varier, Yaacov Ben-David, Jialei Song, Anling Hu, Babu Gajendran, Chunlin Wang, Yanmei Li
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-18 (2021)
Journal of Experimental & Clinical Cancer Research : CR
Journal of Experimental & Clinical Cancer Research : CR
Immunotherapeutic treatments are gaining attention due to their effective anti-tumor response. Particularly, the revolution of immune checkpoint inhibitors (ICIs) produces promising outcomes for various cancer types. However, the usage of immunothera
Autor:
Huimin Tao, Jinti Lin, Kaishun Xia, Chao Qian, Zhengming Yang, Libin Jin, Tiecheng Wang, Bing Liu, Ankai Xu, Jiakang Jin, Jianan Lou, Wei Yu
Publikováno v:
Cancer Cell International, Vol 21, Iss 1, Pp 1-13 (2021)
Cancer Cell International
Cancer Cell International
As the essential sexual hormone, estrogen and its receptor has been proved to participate in the regulation of autoimmunity diseases and anti-tumor immunity. The adjustment of tumor immunity is related to the interaction between cancer cells, immune
Publikováno v:
Cancer Cell International, Vol 21, Iss 1, Pp 1-15 (2021)
Cancer Cell International
Cancer Cell International
Background Stromal components of the tumor microenvironment contribute to bladder cancer progression, and Cancer-Associated Fibroblasts (CAFs) were reported to play an important role. Accumulating pieces of evidence indicate that CAFs participate in
Publikováno v:
Cancer Cell International, Vol 21, Iss 1, Pp 1-17 (2021)
Cancer Cell International
Cancer Cell International
Programmed death-1/programmed death ligand-1 (PD-1/PD-L1) based immunotherapy is a revolutionary cancer therapy with great clinical success. The majority of clinically used PD-1/PD-L1 inhibitors are monoclonal antibodies but their applications are li
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
BMC Cancer
BMC Cancer
Background Clear cell renal cell carcinoma is susceptible to ferroptosis, and immunotherapy is recently recommended as a priority for the initial treatment of metastatic clear cell renal carcinoma. Increased ferroptosis and immune activation can syne